PFE Form 4: Taraporevala Adds 1,471.743 Deferred Phantom Units
Rhea-AI Filing Summary
Cyrus Taraporevala, a Director of Pfizer Inc. (PFE), reported the acquisition of 1,471.743 phantom stock units on 09/30/2025. The filing shows these units represent deferred director compensation that may be settled in cash or common stock at the director's election following retirement. The units correspond to 1,471.743 underlying shares with an indicated per-share price of $25.48, and the report lists 23,444.776 shares beneficially owned by the reporting person after the transaction. The Form 4 was signed on 10/02/2025 by an attorney-in-fact, Shanice A. Reid.
Positive
- 1,471.743 phantom stock units were acquired and reported on 09/30/2025
- The units are explicitly disclosed as deferred director compensation settled in cash or common stock
Negative
- None.
Insights
Director reported deferred-compensation units equal to 1,471.743 shares on 09/30/2025.
The form documents a grant/acquisition of 1,471.743 phantom stock units that are part of deferred director compensation and will be settled in cash or common stock at the director's election following retirement. This is an administrative disclosure required under Section 16 and signals routine director compensation activity rather than a market trade.
The filing also shows the reporting person holds 23,444.776 shares after the transaction; this figure is the post-transaction beneficial ownership disclosed on the Form 4.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Phantom Stock Units | 1,471.743 | $25.48 | $38K |
Footnotes (1)
- Each unit represents one phantom share of common stock. These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.